COMMUNIQUÉS West-GlobeNewswire

Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

06/03/2025 - 15:30

SARASOTA, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the [...]

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

06/03/2025 - 15:35

Lenox Hill Radiology (LHR) in New York and New Jersey Imaging Network (NJIN) to add Nociscan across multiple sites BROOMFIELD, Colo., March 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) ( [...]

Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel

06/03/2025 - 15:35

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 06, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) announces that, on February 11, 2025, [...]

NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting 2025

06/03/2025 - 15:45

Company announcement no. 3-25 6 March 2025 NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting 2025 The Annual General Meeting of NTG Nordic Transport Group A/S will be held on Friday, 28 March [...]

New report confirms Smith+Nephew’s OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty

06/03/2025 - 16:00

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) [...]

Spectral AI Completes Three Device Installations in Australia

06/03/2025 - 16:36

DALLAS, March 06, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and [...]

New national survey finds most Americans unaware concussions are traumatic brain injuries

06/03/2025 - 17:28

New national survey shows public misconceptions about brain injuries persist and highlight need for education Survey Highlights: 81% of adults in the U.S. do not recognize concussions as traumatic brain injuries. While [...]

protocols.io Integrates with eLabNext’s Digital Lab Platform to Ease Access to and Track Protocol Use in Laboratories

06/03/2025 - 17:56

BOSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Today, protocols.io , a platform that enables academic and industry researchers to record and share up-to-date methods for research, announced that, under eLabNext leadership, [...]

Ipsen - Février 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

06/03/2025 - 18:00

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]

Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

06/03/2025 - 18:00

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]

Webinaire post-ECCO d’OSE Immunotherapeutics Lusvertikimab dans le paysage thérapeutique des MICI : Le point de vue des leaders d’opinion

06/03/2025 - 18:00

Webinaire post-ECCO d’OSE Immunotherapeutics Lusvertikimab dans le paysage thérapeutique des MICI : Le point de vue des leaders d’opinion NANTES, France, 6 mars 2025, 18 heures – OSE Immunotherapeutics a récemment [...]

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

06/03/2025 - 18:00

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD NANTES, France – March 6, 2025, 6:00pm CET - OSE Immunotherapeutics recently hosted a webinar featuring key opinion leaders (KOLs [...]

Informations relatives au nombre total de droits de vote et d’actions composant le capital

06/03/2025 - 18:00

Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 6 mars 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général [...]

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

06/03/2025 - 22:00

Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline [...]

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease

06/03/2025 - 22:01

FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX [...]

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

06/03/2025 - 22:01

– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 [...]

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

06/03/2025 - 22:01

Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC Expansion of investigator sponsored “window of opportunity” trial into newly diagnosed glioblastoma patients [...]

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

06/03/2025 - 22:02

No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study without any modifications. SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. ( [...]

Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results

06/03/2025 - 22:05

TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]